{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:07:58Z","timestamp":1792591678413,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atopic dermatitis (AD), a common chronic inflammatory skin disorder in children, often shows limited response to conventional therapies with potential adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This real-world study evaluated dupilumab\u2014a monoclonal antibody targeting IL-4\/IL-13 signaling\u2014in 59 Chinese pediatric patients (aged 6 months\u201312 years) with moderate-to-severe AD, stratified by body weight. Over a median 33-week follow-up (up to 96 weeks), we dynamically assessed efficacy metrics including Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale, and Dermatology Life Quality Index, alongside systematic surveillance of treatment-emergent adverse events (TEAEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Week 16, 68.97% (40\/58) achieved EASI-75, accompanied by significant symptom relief (68.17% itch reduction; 77.4% quality-of-life improvement). Efficacy persisted beyond Week 16 (&amp;gt;58.82% sustained EASI-75) without age or sex differences. TEAEs occurred in 25.42% (15\/59) of patients, primarily conjunctivitis (10.17%) and paradoxical eczema flares (5.08%). Notably, we report the first pediatric cases of acute rash exacerbation within 72 hours post-initial dose (3 patients, EASI increase: 39.90%\u201361.13%) and a unique late-onset pustular dermatitis with fever.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings confirm dupilumab\u2019s sustained effectiveness and manageable safety in Chinese children with AD while highlighting the need for vigilance against early paradoxical flares and rare inflammatory reactions, providing critical real-world evidence for long-term use in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1644875","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:25:09Z","timestamp":1752729909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China"],"prefix":"10.3389","volume":"16","author":[{"given":"Yue","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study","volume":"190","author":"Tian","year":"2024","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40272-022-00499-x","article-title":"Recent developments and advances in atopic dermatitis: A focus on epidemiology, pathophysiology, and treatment in the pediatric setting","volume":"24","author":"Eichenfield","year":"2022","journal-title":"Paediatr Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02753-1","article-title":"Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis","volume":"41","author":"Paller","year":"2024","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2024.04.006","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Ebisawa","year":"2024","journal-title":"Allergol Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.0069","article-title":"Efficacy of dupilumab in children 6 months to 11 years old with atopic dermatitis: A retrospective real-world study in China","volume":"35","author":"Yang","year":"2024","journal-title":"Dermatitis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2246602","article-title":"A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years","volume":"34","author":"Patruno","year":"2023","journal-title":"J Dermatol Treat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2460578","article-title":"Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study","volume":"36","author":"Rob","year":"2025","journal-title":"J Dermatol Treat"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.06.014","article-title":"Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: A real-world, single-center study","volume":"10","author":"Pagan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae406","article-title":"Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study","volume":"50","author":"Pirov","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae300","article-title":"Dupilumab treatment in paediatric atopic dermatitis (2\u201318 years): Spanish multicentre retrospective real-world study","volume":"50","author":"Iznardo","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1466372","DOI":"10.3389\/fimmu.2024.1466372","article-title":"Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis","volume":"15","author":"Kamal","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab\u00a0and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20107","article-title":"Management of atopic dermatitis in patients non-responsive to dupilumab: A single-centre retrospective-cohort study","volume":"38","author":"Greenzaid","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.alit.2021.07.003","article-title":"Subtypes of atopic dermatitis: From phenotype to endotype","volume":"71","author":"Tokura","year":"2022","journal-title":"Allergol Int"},{"key":"B20","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18276","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/all.15742","article-title":"Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin\u00a0flora in patients with moderate-to-severe atopic dermatitis","volume":"78","author":"Hartmann","year":"2023","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/microorganisms12010224","article-title":"Dupilumab alters both the bacterial and fungal skin microbiomes of patients with atopic dermatitis","volume":"12","author":"Umemoto","year":"2024","journal-title":"Microorganisms"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1644875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:25:10Z","timestamp":1752729910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1644875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1644875"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1644875","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"article-number":"1644875"}}